Diverticulitis: A Pharmacist’s Visual Guide
1. Anatomical Foundation: From Colon to Diverticulum
First, understand the anatomy. Diverticula are herniations or “outpouchings” of the colonic mucosa and submucosa through the muscular wall, typically where blood vessels (vasa recta) penetrate, creating a point of weakness.
Visual 1: The Formation of Diverticula
Normal Colon Wall Colon with Diverticulosis
┌─────────────────────┐ ┌─────────────────────┐
│ Mucosa │ │ Mucosa │ ← Herniation
│ Submucosa │ │ Submucosa───┐ │
│ Muscularis Propria │ → Weak │ Muscularis │ ┌─┐ │ → Diverticulum
│ Serosa │ Point │ Propria │ └─┘ │
└─────────────────────┘ │ Serosa └─────┘
└─────────────────────┘
Key Point: Diverticulosis is the mere presence of these pouches (usually asymptomatic). Diverticulitis is the inflammatory or infectious complication when a diverticulum becomes obstructed (often by a fecalith), leading to micro- or macro-perforation.
2. The Inflammatory Cascade: Uncomplicated Diverticulitis
Obstruction leads to bacterial overgrowth, impaired drainage, and focal inflammation/ischemia. This is a transmural process (affecting all layers).
Visual 2: Pathogenesis of Uncomplicated Diverticulitis
Fecalith Obstructs Neck
↓
Bacterial Overgrowth (E. coli, Bacteroides, etc.)
↓
Mucosal Inflammation & Ischemia
↓
┌───────────────────┴───────────────────┐
↓ ↓
Localized Perforation Confined Inflammation
↓ ↓
Peridiverticular Phlegmon Colonic Wall Thickening
(Hot, tender mass) (Seen on CT)
Pharmacist’s Role: This stage is managed with outpatient oral antibiotics (e.g., amoxicillin-clavulanate, or a fluoroquinolone + metronidazole, though FQs are now 2nd-line), bowel rest, and analgesics. Counsel on adherence, signs of worsening (fever, pain), and the lack of role for chronic mesalamine or rifaximin in acute treatment.
3. Complications: The Spectrum of Complicated Diverticulitis
When inflammation leads to contained or free perforation, the disease becomes “complicated.”
Visual 3: Spectrum of Complicated Diverticulitis
Perforation
┌───────────┴───────────┐
↓ ↓
**Contained** **Free**
(Walled-off by mesentery, (Into peritoneal cavity)
omentum, or other organs)
│
┌───────┴───────┐
↓ ↓
**Abscess** **Fistula**
(Collection of pus) (Abnormal connection to:
→ Bladder [colovesical]
→ Skin [colocutaneous]
→ Vagina [colovaginal])
Pharmacist’s Role in Complications:
- Abscess: Requires CT-guided drainage + IV antibiotics. Antibiotic selection must cover gut flora: Piperacillin-tazobactam, Carbapenems, or 3rd/4th Gen Cephalosporin + Metronidazole. Monitor for sepsis.
- Fistula: Requires elective surgical repair, but antibiotic therapy is needed peri-operatively to control infection.
- Free Perforation & Peritonitis: A surgical emergency. Requires immediate resuscitation, broad-spectrum IV antibiotics, and source control surgery (e.g., Hartmann’s procedure).
4. Key Diagnostic Image for Pharmacists: CT Scan Findings
The gold standard for diagnosis and staging in the hospital is a CT scan with IV and PO contrast.
Visual 4: Interpreting the CT (Pharmacist’s View)
[AXIAL CT VIEW - SIGMOID COLON] ───────────────────────────────────── │ │ │ Colonic Lumen ○○○○ │ │ ○ ○ ┌────┐│ │ Thickened Wall (>4mm)○○○○ │ ││ ← **Diverticulum** │ │ ││ │ **Inflamed Fat** ─┼──┐ ││ (Streaky, hazy appearance │ (Mesenteric stranding) │ │ ││ around colon = "dirty fat") │ │ │ ││ │ **Abscess**┘ │ ││ (Fluid collection with │ │ ││ enhancing rim) │ Peritoneal Fluid └─┘│ │ │ ─────────────────────────────────────
Pharmacist’s Insight: The CT report’s language (“uncomplicated,” “phlegmon,” “abscess,” “extraluminal air”) directly dictates the route, spectrum, and duration of antibiotic therapy you will be preparing or verifying.
5. Pharmacotherapeutic Management Algorithm
Visual 5: Hospital Pharmacist’s Decision Pathway
Patient Presents with LLQ Pain, Fever, Leukocytosis
↓
CT Scan Confirms Diverticulitis
↓
┌───────────────┴───────────────┐
↓ ↓
**Uncomplicated** **Complicated**
(No abscess, perforation, (Abscess, fistula,
obstruction, or fistula) perforation, obstruction)
│ │
**Outpatient Care** **Inpatient Management**
│ │
► Oral Abx (7-10 days) ► **IV Antibiotics:**
- Amox/Clav (875/125 BID) - **Empiric:**
- OR: TMP/SMX + Metronidazole Piperacillin-Tazobactam 3.375g q6-8h
- Avoid opioids (↑ pressure) OR: Cefepime 2g q8h + Metronidazole 500mg q6-8h
OR: Ertapenem 1g daily
► Supportive Care:
- Liquid diet, advance as tolerated **► Target Duration:**
- Acetaminophen for pain - Uncomplicated: 4-7 days IV, then PO to complete 10-14d total
- Complicated: 7-14 days, depending on source control
│ │
└───────────────┬───────────────┘
↓
**Monitor & Counsel**
- Stewardship: De-escalate when C&S allows.
- Transition to PO with clinical improvement (afebrile, WBC down, tolerating diet).
- Discharge Counseling: Complete full course, warn about red flags (fever, worsening pain), discuss long-term prevention (high-fiber diet, avoid NSAIDs).
6. Special Considerations for the Hospital Pharmacist
- Antimicrobial Stewardship: Advocate for short-course therapy (often 4-7 days IV) and timely IV-to-PO switch. Avoid prolonged courses without evidence of ongoing infection.
- Pain Management: Avoid opiates when possible (increase intraluminal pressure). Favor IV acetaminophen and consider ketorolac for severe pain (though NSAIDs are controversial for long-term risk).
- Complication-Specific Therapy:
- Abscess: Antibiotics continue until drainage output minimal and leukocytosis resolves.
- Fistula: Pre-op antibiotics to reduce bacterial load.
- Peritonitis: Empiric, broad-spectrum coverage is critical (e.g., meropenem or piperacillin-tazobactam). Dose adjust for renal/hepatic function.
- Discharge Planning: Ensure appropriate oral antibiotic selection, assess for drug interactions (especially with warfarin, metronidazole and alcohol), and provide clear instructions. Discuss prophylactic therapies (e.g., rifaximin in some countries for recurrent episodes, or fiber supplements) for long-term management, not acute treatment.
Summary for the Pharmacist:
You are a key player in managing diverticulitis by ensuring appropriate empiric antibiotic selection, advocating for stewardship and de-escalation, managing therapy duration and transitions, and counseling on complication recognition and prevention. Your understanding of the anatomical and clinical progression directly informs optimal pharmacotherapy.
